ScholarLens Back to search
2004•The Hematology JournalRequires access

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes

Thomas Prébet, Sophie Ducastelle, Stephan Debotton, Aspasia Stamatoullas, Éric Deconinck, Christophe Fruchart, Nicole Gratecos, Norbert Ifrah, François Dreyfus, Pierre Fenaux, Eric Wattel

Open publisher page 7 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 7 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Mitoxantrone, Cytarabine, Fludarabine, Medicine, Internal medicine, Chemotherapy, Neutropenia, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes — Research Paper | ScholarLens